Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryApr 23, 2019 Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting View HTML Toggle SummaryApr 22, 2019 U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab View HTML Toggle SummaryApr 12, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryApr 08, 2019 Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer View HTML Toggle SummaryApr 02, 2019 Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference View HTML Toggle SummaryMar 05, 2019 Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference View HTML Toggle SummaryMar 04, 2019 Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares View HTML Toggle SummaryFeb 27, 2019 Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock View HTML Toggle SummaryFeb 26, 2019 Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement View HTML Toggle SummaryFeb 25, 2019 Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results View HTML Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
